Javascript must be enabled to continue!
Cofibrins and Fibrin-Intermediates as Indicators of Thrombin Activity in Vivo
View through CrossRef
A cold-precipitable, thrombin-coagulable protein, tentatively designated "cryoprofibrin," was separated from plasma of rabbits treated with
E. coli
endotoxin. It was shown to contain fibrin-intermediates, consisting of fibrinogen that has lost only a portion of the peptides liberated during the conversion of rabbit fibrinogen to fibrin. These peptides have been called cofibrins. On reaction with thrombin, fibrinogen and cryoprofibrin yielded the same amount of cofibrin B (0.9 moles per 220,000 Gm. of fibrin clot); however, cryoprofibrin yielded 30 per cent less cofibrin A than did fibrinogen. Cryoprofibrin and fibrinogen yielded 0.7 and 1.0 moles of cofibrin A per 220,000 Gm. of fibrin, respectively. The deficit of cofibrin A in preference to cofibrin B provides evidence that, cryoprofibrin consists of fibrinogen that had lost cofibrin A by limited action of thrombin, because cofibrin A is liberated from fibrinogen by thrombin more rapidly than is cofibrin B.
Only a small portion of the cryoprofibrin could have been produced by action of thrombin subsequent to exsanguination, because the plasma contained only about one-third of the cofibrin A that had been liberated from fibrin-ogen during its conversion to cryoprofibrin. Accordingly, cryoprofibrin provides a valid measure of thrombin activity in vivo, at least in the endotoxin-treated rabbits.
An alternative approach to measurement of thrombin activity involving recovery of cofibrin A from urine proved inapplicable, because no confibrin A was found to be excreted in urine.
An average of 0.264 ± 0.038 mg. cryoprofibrin per ml. was obtained from plasma of treated rabbits, as compared with 0.044 ± 0.016 mg. of cold-precipitable fibrinogen per ml. of normal plasma. The demonstration of increased thrombin activity after endotoxin treatment, as evidenced by the cryoprofibrin, implicates thrombin in the mechanism of fibrinoid deposition. The demonstration that cryoprofibrin consists of fibrin-intermediates supports Thomas' hypothesis that fibrinoid consists of fibrin-intermediates.
Ovid Technologies (Wolters Kluwer Health)
Title: Cofibrins and Fibrin-Intermediates as Indicators of Thrombin Activity in Vivo
Description:
A cold-precipitable, thrombin-coagulable protein, tentatively designated "cryoprofibrin," was separated from plasma of rabbits treated with
E.
coli
endotoxin.
It was shown to contain fibrin-intermediates, consisting of fibrinogen that has lost only a portion of the peptides liberated during the conversion of rabbit fibrinogen to fibrin.
These peptides have been called cofibrins.
On reaction with thrombin, fibrinogen and cryoprofibrin yielded the same amount of cofibrin B (0.
9 moles per 220,000 Gm.
of fibrin clot); however, cryoprofibrin yielded 30 per cent less cofibrin A than did fibrinogen.
Cryoprofibrin and fibrinogen yielded 0.
7 and 1.
0 moles of cofibrin A per 220,000 Gm.
of fibrin, respectively.
The deficit of cofibrin A in preference to cofibrin B provides evidence that, cryoprofibrin consists of fibrinogen that had lost cofibrin A by limited action of thrombin, because cofibrin A is liberated from fibrinogen by thrombin more rapidly than is cofibrin B.
Only a small portion of the cryoprofibrin could have been produced by action of thrombin subsequent to exsanguination, because the plasma contained only about one-third of the cofibrin A that had been liberated from fibrin-ogen during its conversion to cryoprofibrin.
Accordingly, cryoprofibrin provides a valid measure of thrombin activity in vivo, at least in the endotoxin-treated rabbits.
An alternative approach to measurement of thrombin activity involving recovery of cofibrin A from urine proved inapplicable, because no confibrin A was found to be excreted in urine.
An average of 0.
264 ± 0.
038 mg.
cryoprofibrin per ml.
was obtained from plasma of treated rabbits, as compared with 0.
044 ± 0.
016 mg.
of cold-precipitable fibrinogen per ml.
of normal plasma.
The demonstration of increased thrombin activity after endotoxin treatment, as evidenced by the cryoprofibrin, implicates thrombin in the mechanism of fibrinoid deposition.
The demonstration that cryoprofibrin consists of fibrin-intermediates supports Thomas' hypothesis that fibrinoid consists of fibrin-intermediates.
Related Results
Thrombin Induces Protease Activated Receptor (PAR)-3/-4 Interaction in Human Podocytes
Thrombin Induces Protease Activated Receptor (PAR)-3/-4 Interaction in Human Podocytes
Abstract
INTRODUCTION
Nephrotic Syndrome, one of the most common forms of glomerular disease, is characterized by massive proteinuria with structural ...
Abstract 1645: Characterization of a novel anti-insoluble-fibrin chimeric antibody (AFCA) for cancer stromal target (CAST) therapy and diagnosis.
Abstract 1645: Characterization of a novel anti-insoluble-fibrin chimeric antibody (AFCA) for cancer stromal target (CAST) therapy and diagnosis.
Abstract
Background: A large body of clinicopathological evidence supports the conclusion that abnormal coagulation occurs in a variety of cancers. In the non-malign...
Thrombin interaction with platelet glycoprotein Ib: effect of glycocalicin on thrombin specificity
Thrombin interaction with platelet glycoprotein Ib: effect of glycocalicin on thrombin specificity
We describe here the alteration of thrombin specificity induced by its interaction with glycocalicin. Glycocalicin is the external part of platelet glycoprotein Ib alpha (GPIb alph...
The Association Of Thrombin With Fibrin And Its Solubilization During Plasmic Digestion
The Association Of Thrombin With Fibrin And Its Solubilization During Plasmic Digestion
It has previously been demonstrated that thrombin binds to fibrin during clot formation. We have studied the nature of this association and the fate of bound thrombin during fibrin...
An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation
An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation
Abstract
Hemophilia is a hereditary bleeding disorder caused by intrinsic coagulation pathway deficiencies of Factor VIII (hemophilia A) or Factor IX (hemophilia B)....
Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression
Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression
Abstract
In addition to its role in coagulation, thrombin is involved in the inflammatory process by inducing vessel neutrophilic infiltration. Thrombin induces e...
Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations.
Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations.
Abstract
Abstract 4209
It has been reported that severe coagulopathy following exposure to topical bovine thrombin may be attributed to the impurities...
A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation
Abstract
A novel thrombin inhibitor based on single-stranded (ss) deoxynucleotides with the sequence GGTTGGTGTGGTTGG (thrombin aptamer) has been recently discovered....

